Skip to content
Therapeutic Peptides Expanded 2 intermediate

Trastuzumab Deruxtecan: Oligopeptide Research Reference

Trastuzumab Deruxtecan, a bioactive peptide compound with documented applications in biomedical research, pharmacological studies, and therapeutic development

By Encyclopeptide Editorial | 1 min read
therapeutic-peptides-expanded-2 peptide oligopeptide

Overview

Trastuzumab Deruxtecan is a bioactive peptide with well-characterized properties and therapeutic applications.

Structure

PropertyValue
NameTrastuzumab Deruxtecan
SequenceAnti-HER2 monoclonal antibody conjugated to topoisomerase I inhibitor payload (deruxtecan) via cleavable linker; DAR ~8
Length~1327 amino acids (antibody) + linker-payload
Molecular Weight~153 kDa (antibody-drug conjugate)

| Category | Oncology / Antibody-Drug Conjugate |

Mechanism of Action

Antibody-drug conjugate; anti-HER2 antibody delivers deruxtecan (topoisomerase I inhibitor) to HER2-expressing cells, causing DNA damage and cell death. Bystander effect kills adjacent tumor cells

References

  • Wikipept Peptide Database
  • Primary literature (see individual entries)

Test Your Knowledge

Reinforce what you learned about Trastuzumab Deruxtecan: Oligopeptide Research Reference with interactive quizzes on Wikipept.

Take a Quiz on Wikipept